DEVGEN : receives several shareholder notifications

Regulated information

Syngenta Crop Protection AG notified the Company that it has crossed the 90% threshold upwards, and it now holds 94.11% of the shares of Devgen NV.
Syngenta AG and Syngenta Crop Protection AG on the one hand, and the following respective parties:
(i) Aat Van Herk, Van Herk Global Agri BV and O.G.B.B.A. Van Herk BV, (ii) Rudi Mariën and Biovest Comm VA,
(iii) Maurits Cornelis de Ruiter, Wouter Pieter Johannes de Ruiter, Hendrik Dirk de Ruiter Jr and Madeli Participaties BV, and
(iv) Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen NV, on the other hand, notified the Company that their agreement to act in concert was terminated
upon settlement of the initial acceptance period of Syngenta's bid on 17 December 2012. The
participations of the parties mentioned under (i) to (iv) are now each time 0%.
Furthermore, both Monsanto Company and Water Island Capital LLC notified the Company that they have crossed the 3% threshold downwards.
For further details on the transparency declarations received by the Company, reference is made to the website www.devgen.com (investor relations).

Devgen is shaping the field of hybrid rice in India and Southeast Asia and helps farmers meet the productivity increases needed to grow more food on less land using fewer inputs. Thereto, Devgen is using advanced biotechnology and molecular breeding technology to develop next generation hybrid rice seeds:
- Devgen is developing the next generation of hybrid rice, improving yield, seed productivity, grain quality, and tolerance to biotic and abiotic stress factors. Devgen strongly believes that this hybrid rice technology has the potential to drive the accelerated conversion of conventional rice to hybrid rice.

1

- Anticipating the need to increase insect and drought/heat tolerance in rice to a level that is beyond what can be achieved with traditional breeding, Devgen is creating a portfolio of biotech traits using own technology as well as in-licensed technologies.
- Devgen has established an integrated seed business in India and Southeast Asia through which its rice crops and technologies reach the market. In India, Devgen has complemented its hybrid rice business with three other strategic crops that it produces with its own technologies: hybrid sorghum, pearl millet and sunflower.
Devgen innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. Since 1997, Devgen has conducted pioneering research in RNAi-based crop protection applications and has developed enabling technology, RNAi sprays and RNAi-based biotech traits for itself and on behalf of corporate partners.
In its Crop Protection unit, Devgen has developed a novel nematicide, an agrochemical product that protects crops from damage by parasitic nematodes and has superior environmental and worker exposure profile compared to existing solutions. This product is currently sold in Turkey and was recently introduced on the market in the US.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), and has subsidiaries in Singapore, Hyderabad (India), Yogyakarta (Indonesia), General Santos (the Philippines) and Delaware (US), totaling around 250 staff.

Or visit: www.devgen.com

This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other

factors which might cause the actual results, performance or achievements of Devgen to be

2

materially different from any future results or achievements expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, among others: agricultural risks and difficulties, including weather factors, diseases and pests, the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; political, economic and social developments in countries where Devgen operates and other risks and factors detailed in the company's most

recent annual report.

These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for

any securities issued by Devgen nv.

3

distributed by